Krsnaa Diagnostics Beheer
Beheer criteriumcontroles 2/4
Momenteel beschikken wij niet over voldoende informatie over de CEO.
Belangrijke informatie
Mitesh Dave
Algemeen directeur
n/a
Totale compensatie
| Percentage CEO-salaris | n/a |
| Dienstverband CEO | less than a year |
| Eigendom CEO | n/a |
| Management gemiddelde ambtstermijn | 2.6yrs |
| Gemiddelde ambtstermijn bestuur | 3.6yrs |
Recente managementupdates
Recent updates
Krsnaa Diagnostics' (NSE:KRSNAA) Dividend Is Being Reduced To ₹2.50
Sep 06
Krsnaa Diagnostics (NSE:KRSNAA) Has Announced That Its Dividend Will Be Reduced To ₹2.50
Aug 23Krsnaa Diagnostics Limited (NSE:KRSNAA) First-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year
Aug 10Krsnaa Diagnostics' (NSE:KRSNAA) Dividend Is Being Reduced To ₹2.50
Aug 09Krsnaa Diagnostics Limited's (NSE:KRSNAA) 28% Jump Shows Its Popularity With Investors
Jul 05Here's What To Make Of Krsnaa Diagnostics' (NSE:KRSNAA) Decelerating Rates Of Return
Jun 16We Think That There Are More Issues For Krsnaa Diagnostics (NSE:KRSNAA) Than Just Sluggish Earnings
May 26Is Krsnaa Diagnostics (NSE:KRSNAA) A Risky Investment?
Mar 14Krsnaa Diagnostics Limited Just Missed Earnings - But Analysts Have Updated Their Models
Feb 16Krsnaa Diagnostics (NSE:KRSNAA) Will Pay A Larger Dividend Than Last Year At ₹2.75
Aug 31Krsnaa Diagnostics (NSE:KRSNAA) Will Pay A Larger Dividend Than Last Year At ₹2.75
Aug 17Returns On Capital Are Showing Encouraging Signs At Krsnaa Diagnostics (NSE:KRSNAA)
Jun 03Revenue Miss: Krsnaa Diagnostics Limited Fell 6.4% Short Of Analyst Revenue Estimates And Analysts Have Been Revising Their Models
Feb 17Take Care Before Diving Into The Deep End On Krsnaa Diagnostics Limited (NSE:KRSNAA)
Feb 16Krsnaa Diagnostics' (NSE:KRSNAA) Anemic Earnings Might Be Worse Than You Think
Nov 17CEO
Mitesh Dave
less than a year
Tenure
Mr. Mitesh Dave is Group Chief Executive Officer of Krsnaa Diagnostics Limited from June 1, 2024. Mr. Mitesh Dave has two decades of diverse industry experience. His track record spans FMCG, OTC, Pharmaceu...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Executive Chairman | 3.6yrs | ₹25.90m | 24.87% ₹ 7.4b | |
| Chief Financial Officer | 3.8yrs | ₹3.00m | geen gegevens | |
| Company Secretary & Compliance Officer | 1.3yrs | ₹1.33m | geen gegevens | |
| Joint MD | 5.8yrs | ₹54.40m | 0.68% ₹ 203.6m | |
| Group Chief Executive Officer | less than a year | geen gegevens | geen gegevens | |
| National Sales Head | no data | geen gegevens | geen gegevens | |
| Vice President | no data | ₹2.99m | geen gegevens |
2.6yrs
Gemiddelde duur
41yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van KRSNAA wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.6 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Executive Chairman | 3.6yrs | ₹25.90m | 24.87% ₹ 7.4b | |
| Joint MD | 5.8yrs | ₹54.40m | 0.68% ₹ 203.6m | |
| Independent Director | 2.5yrs | ₹1.15m | geen gegevens | |
| Non Executive Director | no data | geen gegevens | geen gegevens | |
| Independent Director | no data | ₹1.05m | geen gegevens | |
| Independent Director | no data | ₹1.00m | geen gegevens | |
| Independent Director | no data | ₹1.00m | geen gegevens |
3.6yrs
Gemiddelde duur
68yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van KRSNAA wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.6 jaar).